Marc R. Arnone

A biochemical rationale for the anticancer effects of Hsp90 inhibitors: Slow, tight binding inhibition by geldanamycin and its analogues

A. King, R. Copeland, P. Tummino, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors.

Alastair J. King, Alex G. Waterson, A. Waterson, 2013, ACS medicinal chemistry letters.

Abstract B88: A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B‐RafV600E mutation

A. Waterson, A. King, B. Heidrich, 2009 .

Identification of Peptide Substrates for Human MMP-11 (Stromelysin-3) Using Phage Display*

S. P. Seitz, C. Albright, M. Kendall, 2003, Journal of Biological Chemistry.

Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.

Chong-Hwan Chang, Chong-Hwan Chang, G. Trainor, 2004, Journal of medicinal chemistry.

Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions

A. King, J. Erhardt, D. Uehling, 2013, PloS one.

Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay.

Ronald D Snyder, R. Snyder, Marc R. Arnone, 2002, Mutation research.

Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup.

A. Waterson, O. Rossanese, A. King, 2011, Bioorganic & medicinal chemistry letters.